Cardiac Replacement with a Total Artificial Heart as a Bridge to Transplantation

Copeland, Jack G.; Smith, Richard G.; Arabía, Francisco A.; Nolan, Paul E.; Sethi, Gulshan K.; Tsau, Pei H.; McClellan, Douglas; Slepian, Marvin J.

doi:10.1056/nejmoa040186

Cited by 463 publications

(227 citation statements)

References 11 publications

(23 reference statements)

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…Despite such disheartening results, some surgeons have continued to use the device with some degree of success. Jack Copeland, for example, has demonstrated that using an artifi cial heart as a bridge to cardiac transplantation can result in signifi cant increases in survival time to transplantation and improved survival after transplantation (25). Kolff , in his remaining years, maintained his enthusiasm for the total artifi cial heart and felt that its ultimate success only required better design and better medical management.…”

Section: The Total Artificial Heartmentioning

confidence: 99%

Saving Lives, Not Sacrificing Them: The Inevitable Clash Between Medical Research and the Protection of Medical Subjects

Weisse¹

2013

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

Section: The Total Artificial Heartmentioning

confidence: 99%

Saving Lives, Not Sacrificing Them: The Inevitable Clash Between Medical Research and the Protection of Medical Subjects

Weisse¹

2013

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

“…Die Implantation eines CardioWest kann u. a. in Fällen von ausgedehnten akuten Myokardinfarkten (AMI), Tumoren im Herzen oder auch ausgedehnten Thromben in beiden Herzkammern in Erwägung gezogen werden. Copeland et al berichtete in einer multizentrischen Studie an 81 BTT-Patienten von einem Einjahresüberleben von 79% sowie einem Einjahresüberleben nach HTx und vorangegangener CardioWestUnterstützung von 86% [28]. Morschuis und Kollegen berichteten über 5 Patienten mit ausgedehntem AMI, welche mit einem TAH-CardioWest gerettet wurden.…”

Section: Introductionunclassified

Fortschritte bei implantierbaren mechanischen Kreislaufunterstüzungssystemen

Krabatsch

Schweiger

Stepanenko

et al. 2011

Herz

View full text Add to dashboard Cite

In recent years, ventricular assist devices (VAD) supporting the left (LVAD), the right (RVAD) or both ventricles (BVAD) have rapidly emerged as the standard of care for advanced heart failure patients. Both the numbers and ages of patients in which they are used are rising worldwide, especially when used as a permanent support (bridge to destination, BTD). Due to the continuing lack of donor organs, these devices now represent a viable alternative to bridge patients to transplantation (BTT), with a 1-year survival rate of 86%. BTD, especially in long-term support, might be a valid, and the sole, option for those patients in whom heart transplantation is contraindicated. Patient selection, pre- and intra-operative preparation, as well as the timing of VAD implantation are important factors critical to successful circulatory support. While BTT remains the goal in the majority of patients, the number of permanent VADs (i. e. BTD) is rising significantly. Although explantation of a VAD system as a bridge to recovery (BTR) can be considered in only a small number of patients, it represents a very special part of this therapy modality.

show abstract

“…This is best summarised in a meta-analysis by Cheng et al, with a conclusion that despite better haemodynamic profile mortality does not decrease significantly [45]. However, these devices may be a bridge to heart transplantation or -if the donor is lacking -to total artificial heart implantation and staged transplantation with an excellent long-term survival [46][47][48].…”

Section: Novel Devices and Areas Of Future Researchmentioning

confidence: 99%

The management of patients with cardiogenic shock

Sadowski¹,

Janion−Sadowska²

2017

View full text Add to dashboard Cite

Cardiogenic shock is a life-threatening condition with a very poor prognosis. Many disorders may contribute to the development of shock. Of them, acute myocardial infarction is the main culprit. Despite tremendous progress in the field of interventional cardiology, in-hospital and long-term mortality still exceeds 50%. Data from large controlled trials on cardiogenic shock are scarce due to ethical reasons. Nevertheless, there is a chance for acceptable long-term survival in patients treated aggressively. The aim of this review is to summarise the key points of differential diagnosis and to emphasise that in most cases of shock due to acute myocardial infarction primary coronary intervention is the treatment of choice. StreszczenieWstrząs kardiogenny jest stanem zagrożenia życia o bardzo złym rokowaniu. Wiele sytuacji klinicznych przyczynia się do rozwoju wstrząsu, ale ostry zawał serca stanowi najczęstszą przyczynę. Pomimo olbrzymiego postępu w kardiologii interwencyjnej śmiertelność szpitalna i długoterminowa nadal przekracza 50%. Z powodów etycznych nie dysponujemy danymi z kontrolowanych badań klinicznych. Niemniej agresywne leczenie stwarza szansę na uzyskanie akceptowalnego poziomu śmier-telności w tej grupie chorych. Celem pracy jest próba podsumowania najważniejszych elementów diagnostyki różnicowej oraz wykazanie, że pilna rewaskularyzacja za pomocą angioplastyki wieńcowej jest leczeniem z wyboru w większości przypadków.

show abstract

Cardiac Replacement with a Total Artificial Heart as a Bridge to Transplantation

Abstract: Implantation of the total artificial heart improved the rate of survival to cardiac transplantation and survival after transplantation. This device prevents death in critically ill patients who have irreversible biventricular failure and are candidates for cardiac transplantation.

Cited by 463 publications

References 11 publications

Saving Lives, Not Sacrificing Them: The Inevitable Clash Between Medical Research and the Protection of Medical Subjects

Saving Lives, Not Sacrificing Them: The Inevitable Clash Between Medical Research and the Protection of Medical Subjects

Fortschritte bei implantierbaren mechanischen Kreislaufunterstüzungssystemen

The management of patients with cardiogenic shock

Contact Info

Product

Resources

About